Geron (GERN) Q2 2026 earnings review
Commercial Pivot Delivers Growth, But Inventory Hits the Bottom Line
Geron's strategic reset is yielding tangible results. Q2 RYTELO net product revenue hit $57.5 million, up 17% YoY and 11% sequentially, confirming the third consecutive quarter of demand growth. Management is executing efficiently on its goal to shift utilization into earlier lines of therapy (now 34% of starts). However, a surprising surge in non-cash inventory-related expenses caused Cost of Goods Sold (COGS) to spike to $9.2 million, keeping net loss flat YoY at $16.7 million despite the revenue acceleration. With guidance reaffirmed at the mid-to-high end of $220-$240 million and a $327 million cash cushion, the fundamental commercial story is intact, even as minor execution and pipeline timeline questions linger.
🐂 Bull Case
The focus on community accounts and 2nd-line MDS patients is driving sustainable, quarter-over-quarter demand growth (+5% QoQ). Geron is successfully capturing market share ahead of HMAs.
Despite 24% revenue growth in H1 2026, total operating expenses actually decreased by 4% YoY. The company is funding its own growth efficiently without immediately tapping equity markets.
🐻 Bear Case
COGS skyrocketed from $1.2M in 25Q2 to $9.2M in 26Q2 strictly due to non-cash inventory write-offs. This directly contradicted the top-line beat and prevented net loss from shrinking.
Geron is actively renegotiating the event threshold for the IMpactMF interim analysis with the FDA. Altering trial parameters this late in the game introduces regulatory risk and timeline uncertainty.
⚖️ Verdict: 🟢
Bullish. The 11% sequential revenue growth proves the commercial machinery is functioning well. While the inventory write-off is an optical headwind, the underlying shift toward longer-duration 2nd-line patients establishes a robust foundation for the back half of the year.
Key Themes
Shift to Second-Line Patient Population Accelerating
The core of Geron's turnaround strategy—moving RYTELO usage from heavily pre-treated 3rd/4th line patients into the 2nd-line setting—is working. First and second-line patient starts reached 34% on a rolling 12-month basis, an accelerating trend compared to 33% in Q1 and 30% two quarters ago. This shift is critical because earlier-line patients stay on therapy longer, directly increasing the lifetime value of each prescription.
Community Account Breadth Expanding
Geron increased its prescribing accounts by roughly 8% in Q2, bringing the total footprint to approximately 1,575 accounts. Management specifically noted that high-tier community accounts are responding well to their targeted omnichannel '3D surround sound' engagement. This expanding breadth is a stable growth driver.
Real-World Evidence Validating RYTELO Profile
At EHA 2026, Geron presented the first real-world evidence from the Moffitt Cancer Center. The data showed that clinical efficacy and safety in advanced, heavily transfusion-dependent LR-MDS patients (including post-luspatercept failures) were consistent with the Phase 3 IMerge trial. This external, third-party validation serves as a powerful driver to lower adoption barriers for hesitant prescribers.
Spike in Cost of Goods Sold from Inventory Write-offs
A massive negative data point in an otherwise clean quarter: COGS jumped from $1.2M in Q2 2025 to $9.2M in Q2 2026. Management attributed this entirely to 'non-cash inventory-related expenses.' While non-cash, write-offs of this magnitude point to potential supply chain friction or miscalculations in production scaling that warrant strict monitoring.
Gross-to-Net Deductions Stabilizing at Elevated Levels
Gross-to-net (GTN) deductions came in at 20.7% for Q2. While slightly lower than Q1's 21%, it is a drastic step up from 15.3% a year ago. Management maintained guidance that GTN will hover in the low-to-mid 20s for the remainder of 2026 due to higher 340B utilization and GPO contracting. This structural margin compression acts as a permanent ceiling on net revenue realization.
IMpactMF Interim Analysis Threshold Modification
The Phase 3 IMpactMF trial (telomerase inhibitor imetelstat in myelofibrosis) is approaching its one-year post-enrollment mark. Management disclosed they are evaluating a 'modification to the event threshold for the interim analysis' with regulators to ensure it is adequate for registration. Altering thresholds while a trial is ongoing introduces risk and raises questions about event accumulation rates.
European Expansion Delayed by Pricing Macro Dynamics
Despite European approval, Geron has no formalized launch plan. Management cited the macro backdrop of MFN (Most Favored Nation) pricing risks and complex HTA models as reasons for caution. The company expects to update the market by year-end on whether they will partner or employ an 'agent commercial' model, leaving a massive potential market entirely untapped for now.
Other KPIs
Stable. Up from $61.5M a year ago, but this was entirely driven by the $8M jump in COGS due to inventory write-offs. Stripping out COGS, OpEx (R&D + SG&A) was perfectly flat YoY at $60.9M. This proves the benefits of the December 2025 workforce reduction are materializing and funding the commercial expansion.
Decelerating cash burn. Down from $341.0 million at the end of Q1. A quarterly burn of roughly $14 million is highly manageable against a $327 million stockpile, validating management's claim that they are funded for the foreseeable future without needing dilutive capital raises.
Guidance
Accelerating. Management explicitly stated they expect to come in at the 'mid-to-high end' of this range. Given H1 2026 revenue was $109.3 million, hitting the high end ($240M) requires $130.7 million in H2, implying an average of ~$65 million per quarter. This requires consistent sequential growth, which they delivered in Q2.
Stable. Reiterated guidance. At the midpoint ($235M), and with H1 OpEx at $121.6M, H2 OpEx is implied to be ~$113.4M. This indicates that spend will actually trend down slightly in the second half of the year, further paving the path to future profitability.
Key Questions
Inventory Write-Off Visibility
COGS spiked to $9.2 million this quarter primarily due to non-cash inventory write-offs. Can you clarify the exact nature of this write-off (e.g., product expiration, manufacturing defect) and why the magnitude was so severe relative to sales?
IMpactMF Protocol Modifications
You noted you are evaluating a modification to the event threshold for the IMpactMF interim analysis. Is this being driven by a slower-than-expected accumulation of OS events, or is it a proactive measure requested by regulatory authorities?
Ex-U.S. Strategy Timeline
With the end-of-year target to announce an EU strategy approaching, how far along are partnership discussions, and is a 'no-launch' scenario still on the table if acceptable pricing cannot be negotiated?